Tolerogenic Dendritic Cells in T1D — PatSnap Eureka
Tolerogenic Dendritic Cells & Immune Tolerance Drug Pipeline in Type 1 Diabetes
From tolDC cell therapy to IL-2/Treg combinations and antigen-specific immunotherapy — explore the full innovation landscape driving immune tolerance strategies in T1D, mapped from patent and academic literature signals.
T1D: Autoimmune Destruction of Pancreatic β-Cells
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease driven by autoreactive destruction of insulin-producing pancreatic β-cells, representing a major unmet medical need where insulin replacement fails to halt the underlying immune pathology. The core pathological event is autoreactive CD4+ and CD8+ T lymphocyte infiltration of the pancreatic islets leading to β-cell destruction, insulin insufficiency, and hyperglycemia.
The convergence of cellular immunotherapy, cytokine biology, and antigen-specific tolerance induction has made tolerogenic dendritic cells (tolDCs), regulatory T cells (Tregs), and related immune modulators among the most actively investigated therapeutic modalities in this space. Multiple retrieved papers from the University of Florida, Université de Sherbrooke, CNRS (France), and Benaroya Research Institute identify deficient IL-2/IL-2R signaling as a central molecular defect in T1D pathogenesis, with downstream consequences for Foxp3+ Treg survival and function.
Retrieved results from life sciences innovation intelligence highlight the PD-1/PD-L1 inhibitory pathway as a critical mediator of pancreatic immune tolerance, with disruption of this axis linked to autoimmune progression. TLR2, TLR4, TLR7, and TLR9 are identified as innate immune receptors involved in initiating diabetogenic DC activation through sensing of apoptotic β-cell molecular patterns.
Innovation activity in this dataset is predominantly literature-driven (academic), with commercial patent activity represented by a single active EP patent from SOTIO A.S. (Prague, Czech Republic). The dataset contains no United States or PCT patent filings, suggesting either that commercial tolDC patent prosecution is underrepresented in this search or that this remains a primarily academically driven field.
Six Active Modality Clusters in the T1D Immune Tolerance Pipeline
From ex vivo tolDC generation to antigen-specific peptide immunotherapy — each modality cluster is mapped by mechanism, evidence base, and clinical development stage.
Tolerogenic Dendritic Cell (tolDC) Therapy
The largest cluster (~20 papers, 1 patent) addresses ex vivo generation and administration of tolDCs. Protocols include cytokine conditioning (IL-10, TGF-β, TSLP), pharmacological agents (vitamin D analogs, tofacitinib, MPLA, 2-deoxy-glucose), and genetic manipulation. SOTIO A.S. holds the only active commercial EP patent describing MPLA-stabilized semi-mature tolDCs loaded with GAD65 and insulin antigens.
Phase I completed (University of Pittsburgh)Low-Dose IL-2 and IL-2/Treg Combination Therapy
Low-dose IL-2 (ld-IL-2) preferentially expands Foxp3+ Tregs, upregulates CTLA-4, ICOS, and GITR on Tregs, and suppresses IFN-γ production by pancreas-infiltrating effector T cells. A CNRS study demonstrated a 5-day ld-IL-2 course reversing established T1D in NOD mice. The Phase I TILT trial combined polyclonal Treg infusion with ld-IL-2 in T1D patients, using single-cell RNA-Seq tracking post-infusion.
Phase I TILT trial (human data)Antigen-Specific Tolerogenic Immunotherapy
Includes peptide/MHC tetramers, Ig-fused mimotopes, tolerogenic antibodies, and multi-peptide intradermal injection. King's College London's randomized placebo-controlled study of six HLA-DRB1*0401-selective β-cell peptides (10, 100, 500 μg) administered intradermally for 24 weeks maintained C-peptide at ≥100% baseline in approximately half of treated subjects. Monoclonal antibody LD96.24 (University of Colorado) targets IAg7-KS20/IAPP complexes.
Early clinical (peptide); preclinical (antibody)PD-1/PD-L1 Checkpoint Pathway Modulation
PD-L1 expression on islet cells, antigen-presenting cells, and Tregs limits self-reactive T cell activation. Massachusetts General Hospital / Harvard Medical School demonstrated PD-L1's unique role in controlling self-reactive T cells in the pancreas; parenchymal PD-L1 expression is critical. The Cleveland Clinic demonstrated that durable euglycemia via neo-islet formation required PD-L1-driven tolerance. Checkpoint inhibitor-induced T1D is used as a disease model by San Raffaele Scientific Institute.
Primarily mechanistic / preclinicalSmall Molecule Immunomodulators Targeting tolDC Generation
JAK inhibitor tofacitinib (Chengdu Medical College) generates semi-mature tolDCs with low proinflammatory cytokine profiles. Novel compound T74 (Konkuk University) — a TGF-β receptor signaling agonist — reduces DC surface molecules and inflammatory cytokines. Nuclear receptor LRH-1/NR5A2 pharmacological activation (2023) reprograms T1D patient macrophages and DCs from pro- to anti-inflammatory/tolerogenic states in human ex vivo and xenotransplantation models.
Preclinical; LRH-1/NR5A2 in human T1D cellsAdoptive Treg Cell Therapy
Both polyclonal and antigen-specific Treg expansion and adoptive transfer are supported by preclinical NOD mouse data and Phase I human trial data. A systematic review (Medical University in Lublin) of 20 immune intervention trials (2010–2021) concluded Tregs play central roles in limiting β-cell destruction. Treg persistence remains a critical technical challenge — the majority of infused Tregs are undetectable at 3 months without ld-IL-2 co-administration.
Phase I (TILT trial); systematic review of 20 trialsPipeline Signals: Clinical Stage & Molecular Target Distribution
Data derived from patent and academic literature records retrieved via PatSnap Eureka. Represents innovation signals within this dataset only.
Therapeutic Modalities by Clinical Development Stage
tolDC cell therapy and Treg/IL-2 combinations are the most clinically advanced modalities; small molecule approaches remain preclinical.
Molecular Target Citation Frequency
GAD65/Insulin B9-23 and the IL-2/Foxp3 axis appear in the greatest number of retrieved results as primary therapeutic targets.
Emerging Combination Strategies in T1D Immune Tolerance
Retrieved results signal five key combination approaches, from dual lymphocyte targeting to metabolic DC reprogramming.
Key Targets, Mechanisms & Evidence Sources
Each target is mapped to its mechanistic role, key evidence institution, and therapeutic relevance in the T1D tolerance pipeline.
| Target | Mechanistic Role | Key Evidence Institution | Therapeutic Relevance |
|---|---|---|---|
| GAD65 / Insulin B9-23 | Primary autoantigenic targets driving pathogenic T cell responses; used to pulse tolDCs and induce antigen-specific Tregs | SOTIO A.S. (patent); China Agricultural University; King's College London | Highest — appear in greatest number of retrieved results; SOTIO EP patent explicitly claims tolDCs pulsed with GAD65 and insulin |
| IL-2 / IL-2R / Foxp3 | Deficient IL-2/IL-2R signaling directly impairs FOXP3 expression maintenance in CD4+CD25+ Tregs; IL-2 gene polymorphisms are T1D susceptibility genes | Benaroya Research Institute; CNRS UMR 7211; University of Florida; University of Sherbrooke | High — ld-IL-2 therapy has reached Phase I clinical trials (TILT trial); IL-2/anti-IL-2 complexes produce near-complete NOD prevention |
| PD-1 / PD-L1 (CD274/B7-H1) | PD-L1 on pancreatic parenchymal cells (not only APCs) is required to prevent autoreactive T cell-mediated destruction; B7-H1-deficient semi-mature DCs exhibit enhanced tolerogenic potential | Massachusetts General Hospital / Harvard Medical School; San Raffaele Scientific Institute; University of Würzburg | High mechanistic relevance; checkpoint inhibitor-induced T1D used as disease model; gene therapy combination approach (Cleveland Clinic) |
| ZnT8 / IAPP (KS20) | Non-insulin autoantigens; new tolerogenic CD8+ T cell epitopes in ZnT8 (aa 158–166 and 282–290); IAPP-derived KS20 is a highly diabetogenic epitope targeted by tolerogenic mAb LD96.24 | New York University Langone School of Medicine; University of Colorado Anschutz Medical Campus | Moderate — expanding the autoantigen target repertoire beyond insulin/GAD65; LD96.24 antibody demonstrates tolerance induction in early and late-stage NOD mice |
Track Emerging Assignees & Academic Groups
SOTIO A.S., Novo Nordisk, Merck, San Raffaele, King's College London — monitor their next filings.
IP & Development Implications for Drug Developers
Key strategic signals derived from retrieved patent and literature records — for IP teams, R&D strategists, and investors evaluating the T1D tolerance space.
SOTIO A.S. EP Patent: Potential IP Chokepoint
SOTIO A.S. holds the only active commercial patent in this dataset (EP jurisdiction) for MPLA-stabilized tolDCs targeting T1D with defined autoantigen loading (GAD65, insulin). Drug developers should assess freedom-to-operate in US, PCT, and Asian jurisdictions — no filings were identified in those jurisdictions within this dataset.
TILT Trial: Most Clinically Advanced Modality
The combination of ld-IL-2 with Treg adoptive transfer (TILT trial) has progressed to Phase I human study, representing the most clinically advanced modality in this dataset. Treg persistence remains a critical technical challenge — the majority are undetectable at 3 months. IL-2 engineering approaches (IL-2/anti-IL-2 complexes, nanoparticle-formulated IL-2) may offer competitive differentiation.
Peptide Immunotherapy: Clinical Proof-of-Concept
Antigen-specific peptide immunotherapy has demonstrated clinical proof-of-concept (King's College London multi-peptide trial), preserving C-peptide in approximately half of HLA-DRB1*0401-positive recent-onset T1D patients. Expansion to broader HLA types and earlier-stage (pre-symptomatic) disease represent logical next development steps signaled by retrieved data.
Immunometabolism: Next-Generation tolDC Manufacturing Signal
The immunometabolism of DCs (OXPHOS vs. glycolysis balance, 2-DG stabilization, LRH-1/NR5A2-mediated reprogramming) is emerging as a mechanistically tractable approach to generate stable tolDCs resistant to inflammatory conversion. Investors evaluating next-generation cell therapy manufacturing platforms should monitor this small molecule–assisted tolDC stabilization space as a potential technical differentiator from first-generation cytokine-based protocols.
From NOD Mouse Models to Phase I Human Trials
Retrieved results contain six explicit clinical or translational signals. The Phase I tolDC trial at the University of Pittsburgh (2011) administered autologous tolDCs (10M cells intradermally, 4 doses over 6 weeks) to 10 adult T1D patients, establishing feasibility and safety as the primary endpoint. A patent landscape analysis via PatSnap Eureka confirms this as the first completed Phase I study in this dataset.
The multi-peptide β-cell antigen intradermal immunotherapy trial (King's College London, 2022) — a randomized placebo-controlled study — administered six HLA-DRB1*0401-selective β-cell peptides at 10, 100, and 500 μg monthly for 24 weeks. C-peptide was maintained at ≥100% baseline in approximately half the treated group versus decline in all placebo subjects, representing clinical proof-of-concept for antigen-specific approaches.
The Phase I TILT trial (2021) combined autologous polyclonal Tregs with one or two 5-day courses of recombinant human ld-IL-2 in T1D patients. Multiparametric flow cytometry and single-cell RNA-Seq tracked immune population dynamics post-infusion, generating the richest mechanistic human dataset in this pipeline. NIH-registered trials across autoimmune diseases confirm five completed clinical trials with tolDC outcomes.
No retrieved results describe Phase II or Phase III trial outcomes, approved therapies for T1D based on tolDC or Treg approaches, or regulatory submissions. Autoimmune hepatitis-specific clinical signals were absent from all retrieved results. The life sciences pipeline intelligence from PatSnap Eureka can surface emerging AIH signals not captured in this snapshot.
The most recent translational signal is the LRH-1/NR5A2 activation study (2023) — pharmacological LRH-1/NR5A2 activation tested on macrophages and DCs derived from T1D patients (human ex vivo), representing an IND-enabling translational signal for this nuclear receptor agonist approach and the most recent innovation signal in this dataset.
Commercial & Academic Innovation Leaders in This Dataset
Innovation activity is predominantly literature-driven. One active commercial EP patent and multiple high-output academic institutions define the current landscape.
SOTIO A.S.
The only biopharma assignee with both a patent filing and a published paper in this dataset. The EP patent (active) describes MPLA-stabilized semi-mature tolDCs for T1D with autoantigen loading (GAD65, insulin) and specific embodiments addressing HbA1c-defined patient populations. The associated 2019 paper reviews NOD mouse model evidence for tolDC optimization.
1 active EP patent · 1 paperUniversity of Pittsburgh & San Raffaele Scientific Institute
University of Pittsburgh / Carnegie Mellon: Multiple papers on DC subsets, Phase I tolDC trial data, and clinical tolDC characteristics. San Raffaele / Telethon Institute: Multiple papers describing DC-10 (IL-10-differentiated human tolDCs), Tr1 cell induction, PD-1/PD-L1 pancreatic tolerance, and gene therapy approaches.
Highest academic output in datasetKing's College London, University of Barcelona & University of Sherbrooke
King's College London: Randomized placebo-controlled multi-peptide intradermal immunotherapy trial. University of Barcelona: IL-2/anti-IL-2 complexes + peptide/MHC tetramers combination producing near-complete diabetes prevention in NOD mice. University of Sherbrooke: IL-2 tolerogenic properties, TSLP-conditioned DCs, and Treg differentiation in NOD mice.
European academic clusterHarvard Medical School / MGH & Novo Nordisk Research Center
Harvard Medical School / Massachusetts General Hospital: Papers on PD-L1 peripheral tolerance and insulin-coupled APC therapy. Novo Nordisk Research Center (Seattle): Academic-style paper on LD IL-2 and antigen-specific Treg therapy for T1D, discussing the therapeutic window and early clinical validation across multiple autoimmune indications including hepatitis C virus-induced vasculitis and graft-versus-host disease.
US academic + industry-adjacentTolerogenic Dendritic Cells in T1D — Key Questions Answered
Tolerogenic dendritic cells (tolDCs) are ex vivo-generated immune cells that suppress autoreactive T cell responses. Mechanistically, tolDCs function by suppressing costimulatory molecule expression (CD80, CD86, CD40); secreting anti-inflammatory cytokines (IL-10, TGF-β); inducing Foxp3+ Tregs and type 1 regulatory T cells (Tr1); and promoting T cell anergy rather than effector differentiation. Multiple protocols exist including cytokine conditioning with IL-10, TGF-β, and TSLP, as well as pharmacological agents such as vitamin D analogs, tofacitinib, and monophosphoryl lipid A (MPLA).
Phase I clinical trials have been completed. A randomized double-blind Phase I study at the University of Pittsburgh administered autologous tolDCs (10M cells intradermally, 4 doses over 6 weeks) to 10 adult T1D patients, establishing safety. A review from Carnegie Mellon University confirms clinical trials of tolDCs are ongoing for T1D, rheumatoid arthritis, MS, and Crohn's disease, with reported outcomes including increases in Foxp3+ Tregs. No Phase II or Phase III trial outcomes or approved therapies are described in retrieved results.
The primary autoantigenic targets driving pathogenic T cell responses include insulin (specifically the B9-23 peptide), glutamic acid decarboxylase (GAD65), zinc transporter ZnT8, islet amyloid polypeptide (IAPP/KS20), and the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). The SOTIO patent explicitly describes tolDCs pulsed with GAD65 polypeptide or insulin polypeptide as therapeutic agents.
Low-dose IL-2 (ld-IL-2) acts as a preferential Treg-expanding agent that avoids the broad immunosuppression of higher doses. Retrieved results report that ld-IL-2 increases pancreatic Foxp3+ Treg numbers, upregulates CTLA-4, ICOS, and GITR expression on Tregs, and suppresses IFN-γ production by pancreas-infiltrating effector T cells. A CNRS study demonstrated a 5-day low-dose IL-2 course reversing established T1D in NOD mice with long-lasting effects through pancreatic Treg expansion.
SOTIO A.S. (Prague, Czech Republic) holds the only active commercial patent in this dataset — an EP patent describing MPLA-stabilized semi-mature tolDCs loaded with T1D-associated antigens (GAD65, insulin) for defined HbA1c patient populations. This represents a potential IP chokepoint for monocyte-derived tolDC manufacturing with MPLA adjuvant in Europe. The dataset contains no United States or PCT patent filings in this space.
Several combination strategies are described in retrieved results: Treg adoptive transfer combined with ld-IL-2 (the TILT trial, Phase I); IL-2/anti-IL-2 antibody complexes combined with peptide/MHC tetramers producing near-complete diabetes prevention in NOD mice; anti-CD20 combined with oral anti-CD3 reversing diabetes in more than 60% of newly diagnosed NOD mice; and PD-L1 overexpression combined with Neurogenin3/betacellulin-induced neo-islet formation for durable euglycemia reversal.
Still have questions? Let PatSnap Eureka search the full T1D patent and literature database for you.
Ask PatSnap Eureka About tolDC TherapiesMap the Complete T1D Immune Tolerance Pipeline — Patents, Literature & Clinical Signals
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D in immunology, cell therapy, and autoimmune disease.
References
- Identification of Candidate Tolerogenic CD8+ T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model — New York University Langone School of Medicine, 2016
- Central Role for Interleukin-2 in Type 1 Diabetes — University of Florida, 2011
- Type I Diabetes-Associated Tolerogenic Properties of Interleukin-2 — University of Sherbrooke, 2011
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells — CNRS UMR 7211, 2010
- Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects — Benaroya Research Institute at Virginia Mason, 2009
- Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes — San Raffaele Scientific Institute, 2020
- Tissue expression of PD-L1 mediates peripheral T cell tolerance — Massachusetts General Hospital / Harvard Medical School, 2006
- Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway — Harvard University, 2006
- Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes — Universidad Autónoma "Benito Juárez" de Oaxaca, 2021
- Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? — SOTIO (Prague), 2019
- Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes — Novo Nordisk Research Center, 2016
- The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes — Phase I TILT trial, 2021
- Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes — King's College London, 2022
- A Novel Tolerogenic Antibody Targeting Disulfide-Modified Autoantigen Effectively Prevents Type 1 Diabetes in NOD Mice — University of Colorado Anschutz Medical Campus, 2022
- Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers — University of Barcelona, 2018
- Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance — Chengdu Medical College, 2016
- Synthetic TGF-β Signaling Agonist-Treated Dendritic Cells Induce Tolerogenicity and Antirheumatic Effects — Konkuk University, 2022
- LRH-1/NR5A2 Activation Rewires Immunometabolism Blunting Inflammatory Immune Cell Progression in Individuals with Type 1 Diabetes — 2023
- Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients — University of Pittsburgh School of Medicine, 2011
- Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1 — Medical University in Lublin, 2021
- Tolerogenic dendritic cells, methods of producing the same, and uses thereof — SOTIO A.S., EP Patent (active), 2020
- PD-L1–Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice — Cleveland Clinic, 2014
- National Institutes of Health (NIH) — Clinical trial registry and T1D research funding
- World Health Organization (WHO) — Global diabetes burden and classification
- Nature — Peer-reviewed immunology and autoimmune disease research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.